Behavioral Treatments for Self-Harm
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores two types of behavioral treatments for individuals with intellectual disabilities who engage in self-injurious behavior (SIB). SIB can cause serious harm, and the study targets subtypes of SIB that are difficult to treat with usual methods. Participants will receive either a combination treatment or noncontingent reinforcement (NCR), which involves providing rewards not linked to specific behaviors, to determine which is more effective. This trial suits individuals aged 4 to 25 who exhibit Subtype 2 or 3 automatically maintained SIB and are admitted to the Neurobehavioral Unit Inpatient program at the Kennedy Krieger Institute. As an unphased trial, this study offers a unique opportunity to contribute to groundbreaking research in behavioral treatments.
Will I have to stop taking my current medications?
The trial information does not specify whether participants need to stop taking their current medications.
What prior data suggests that these behavioral treatments are safe for individuals with ASIB?
Research has shown that both combination treatment and noncontingent reinforcement (NCR) are generally well-tolerated by patients. Studies have found that combination treatment significantly reduces self-harming behavior. Behavioral therapies, including combination treatments, lead to quick symptom improvements. Various studies have used these treatments safely, with no major side effects reported.
A review of multiple studies found NCR to be very effective in reducing problem behaviors, including self-harm. Most studies report strong positive effects without major safety concerns. NCR has effectively decreased self-harming behavior, even when used with other safety measures to protect participants.
Both treatments have shown promise in improving safety and reducing harmful behaviors. While no treatment is without risk, current research suggests these approaches are safe and effective for many patients.12345Why are researchers excited about this trial's treatments?
Researchers are excited about these behavioral treatments for self-harm because they offer a fresh approach compared to the traditional methods, which often include medications like antidepressants and therapy sessions. The combination treatment and Noncontingent Reinforcement (NCR) focus on altering behavior through positive reinforcement and consistent support, which could potentially reduce self-harming actions more effectively. Unlike medications that primarily target chemical imbalances, these methods aim to directly modify the behavior patterns that lead to self-harm. This approach could provide a more immediate and sustainable way to help individuals manage and reduce self-harming behaviors.
What evidence suggests that this trial's treatments could be effective for self-injurious behavior?
This trial will compare different behavioral treatments for self-harm. Research has shown that a combination of therapies, especially Dialectical Behavior Therapy (DBT), can effectively reduce self-harm behaviors. Studies have found that DBT significantly decreases the frequency of non-suicidal self-injury (NSSI).
Noncontingent Reinforcement (NCR) is another method studied in this trial. A review of several studies found that NCR greatly reduces problem behaviors. This approach provides regular positive reinforcement regardless of the person's actions, which helps lessen problematic behaviors.
Both treatments in this trial have shown promising results in reducing self-injurious behaviors, offering potential relief for those facing these challenges.26789Who Is on the Research Team?
Louis P Hagopian, PhD
Principal Investigator
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Are You a Good Fit for This Trial?
This trial is for individuals aged 4-25 with intellectual disabilities who are inpatients at the Kennedy Krieger Institute and show specific types of self-injurious behavior. It's not open to non-English speakers, foster children, or those with medical conditions that could affect their participation or increase risk.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Pre-Treatment Assessment
Identify competing stimuli, tasks, and self-control equipment for treatment-resistant subtypes of ASIB
Treatment
Participants receive either Noncontingent Reinforcement (NCR) or Combination Treatment (CT) targeting treatment-resistant subtypes of ASIB
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Combination Treatment
- Noncontingent Reinforcement (NCR)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Lead Sponsor